Ken Griffin Mirati Therapeutics, Inc. Call Options Transaction History

Citadel Advisors LLC

6 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2023 Feb 14, 2024	SELL	$41.99 - $62.38 $860,795 - $1.28 Million	-20,500 Reduced 47.9%	22,300 $1.31 Million
Q3 2023 Nov 14, 2023	BUY	$27.8 - $45.35 $861,800 - $1.41 Million	31,000 Added 262.71%	42,800 $1.86 Million
Q2 2023 Aug 14, 2023	BUY	$36.13 - $49.49 $126,455 - $173,215	3,500 Added 42.17%	11,800 $426,000
Q1 2023 May 15, 2023	SELL	$36.54 - $54.26 $4.48 Million - $6.65 Million	-122,500 Reduced 93.65%	8,300 $308,000
Q4 2022 Feb 14, 2023	BUY	$41.27 - $98.62 $2.15 Million - $5.14 Million	52,100 Added 66.2%	130,800 $5.93 Million
Q3 2022 Nov 14, 2022	SELL	$59.5 - $86.7 $113,050 - $164,730	-1,900 Reduced 2.36%	78,700 $5.5 Million

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.